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Background: Gastrokine-1 (GKN1), a secreted protein, is specifically expressed in gastric mucosa to protect and
maintain the integrity of gastric epithelium. The present study investigated differential expression of GKN1 in
normal, precancerous, and cancerous gastric tissues, and explored the biological functions of GKN1 protein in
gastric cancer cells.
Methods: RT-PCR, Western blot, and immunohistochemistry were performed to detect GKN1 expression in normal,
precancerous, cancerous gastric tissues and seven gastric cancer cell lines. Gene transfection was used to restore
GKN1 expression in gastric cancer AGS cells. Phenotypic changes (i.e., cell viability, apoptosis, cell cycle modulation,
and sensitivity of gastric cancer cells to fluorouracil (5-FU)) were assayed in the transfected cells. DNA microarrays
were used to analyze expression changes of apoptosis-related genes.
Results: Significant downregulation or absence of GKN1 expression in seven gastric cancer cell lines were detected
and progressive decrease of GKN1 expression from normal mucosa, precancerous tissue, to cancer tissues was
observed. Moreover, restoration of GKN1 expression suppressed gastric cancer cell viability and induced the cells to
undergo apoptosis. GKN1 expression also enhanced tumor cell sensitivity to 5-FU treatment. Moreover, it was found
that GKN1 expression in AGS cells modulated expression of 19 apoptosis-related genes.
Conclusions: Expression of GKN1 is progressively lost from normal mucosa, precancerous to cancerous gastric
tissues, while restoration of GKN1 expression induces gastric cancer cells to undergo apoptosis, and enhances
sensitivity of gastric cancer cells to 5-FU-induced apoptosis.
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Gastric cancer is the fourth most common cancer, and
one of the leading causes of cancer-related deaths in the
world [1-3]. Although there have been a number of re-
cent research advances in gastric cancer, such as
improvements in early detection, advances in molecular
research, newer surgery techniques, and more chemo-
therapy options, the overall survival rate for patients
with gastric cancer has not been significantly improved.
Therefore, research that focuses on new biological* Correspondence: chenminhu@vip.163.com
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reproduction in any medium, provided the ormarkers of early detection, new agents of possible genetic
target, and further elucidating the molecular mechanisms
will contribute to the therapeutic strategies.
Gastrokine-1 (GKN1), a novel protein cloned by a
Japanese group in 2000 [4], is exclusively expressed in
the gastric epithelium and easily biopsied. During gastric
carcinogenesis, the GKN1 protein is downregulated in
comparison to abundant expression in normal gastric
mucosa [5]. Thus, this protein may be a potential bio-
logical marker for early detection of gastric cancer.
Functionally, GKN1 promotes the maturation of gastric
mucosa, and maintains the integrity of gastric mucosal
epithelium through mitogenic and mutagenic abilities
[6]. GKN1 may also protect the intestinal mucosal
barrier by acting on specific tight junction proteins andd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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GKN1 protein contains a BRICHOS domain, which is
associated with dementia, respiratory distress and cancer
[8]. Therefore, the deficiency of GKN1 will result in the
instability of gastric mucosa. The risk factors such as
H. pylori can contribute to the down regulation of
GKN1; meanwhile induce ulceration and cancer [9,10].
In addition, several studies observed that GKN1 expres-
sion was down regulation in gastric atrophy and intes-
tinal metaplastic lesions and even absence in gastric
cancer [5,11]. These studies demonstrate that GKN1
may play a key role in the gastric cancer progression.
In the present study, we examined GKN1 expression
in tissue specimens of normal, premalignant, and malig-
nant gastric mucosa. We then investigated the possible
biological functions of GKN1 in gastric cancer cells by
assessing the resulting phenotypic changes in GKN1
transfected cells. The primary aim of this study was to
identify and characterize GKN1 as a potential tumor
suppressor in gastric cancer.Methods
Tissue specimens
Tissue specimens of atrophic gastritis, intestinal meta-
plasia, dysplasia, and gastric cancer were obtained from
a total of 159 patients in our university hospitals. The
premalignant lesions were from patients who underwent
upper gastrointestinal endoscopy. Tissues of gastric
tumors and their corresponding distant non-tumor tis-
sues were collected from 39 gastric cancer patients who
underwent surgery (Table 1). None of the gastric cancer
patients received preoperative chemotherapy or radio-
therapy. In addition, 20 healthy volunteers were also
obtained for this study and these individuals visited our
hospital for routine physical examinations and were con-
firmed to be negative for H. pylori infection by using
13C-urea breath test. All participants signed a written
informed consent, and our Institutional Review Board
approved the work. All tissue specimens were histologi-





mean ± SDMale Female
Healthy volunteers 20 10 10 44.6 ± 12.7
Atrophic gastritis 40 25 15 50.2 ± 10.8
Intestinal metaplasia 40 26 14 60.9 ± 13.5
Dysplasia 40 30 10 64.0 ± 11.4
Gastric cancer 39 23 16 53.0 ± 10.0Gastric cancer cell lines
Seven gastric cancer cell lines, MKN28, MKN45, AGS,
N87, SNU 1, SNU 16 and KATO, were obtained from
the Riken Cell Bank (Tsukuba, Japan) or the American
Type Culture Collection (Manassas, VA, USA). Cells
were cultured in RPMI 1640 medium containing 10%
fetal bovine serum (Hyclone, Logan, USA), and main-
tained at 37°C in a humidified 5% CO2 atmosphere.
RNA isolation and RT-PCR
Gastric tissue specimens were homogenized with an
ultrasound homogenizer. Total RNA from tissues and
tumor cells was isolated using the Qiagen RNeasy Mini
Kit (Qiagen, Hilden, Germany) according to the manu-
facturer’s instructions. After quantification, RNA was re-
verse transcribed into cDNA using ReverTra Ace™ Kit
(Toyobo Co., Osaka, Japan). The newly synthesized
cDNA was then amplified by PCR with specific primers
for the GKN1 gene (50-TTTGCTGGACTTCTTGGA-30
and 50-TCGACTTTGTTTGGGTTG-30) or β-actin,
which was used as an internal control. PCR amplifica-
tion was performed under the following conditions: an
initial cycle at 94°C for 5 min, followed by 28 cycles at
94°C for 45 sec, 53°C for 30 sec, and 72°C for 1 min,
with a final extension at 72°C for 7 min. PCR products
were subsequently electrophoresed on a 1.5% agarose
gel, and visualized under a UV transilluminator.
Protein extraction and Western blot
Total cellular protein was extracted from tissue speci-
mens and gastric cancer cells, using a lysis buffer
containing a 1X protease inhibitor cocktail (Roche,
Mannheim, Germany). Protein was quantified using the
BCA Protein Assay Kit (Pierce Biotechnology, Rockford,
USA). Equal amounts of protein were resolved by10%
SDS-PAGE, and electroblotted onto polyvinylidene
difluoride (PVDF) membranes. Membranes were then
blocked in 5% non-fat milk overnight, and the next day,
were incubated for 2 h with a 1:500 dilution of anti-
GKN1 antibody (Abnova, Taipei, China) or a 1:1000 di-
lution of an antibody against beta-actin (Cell Signaling
Technology, Danvers, USA,). After washed with phos-
phate buffered saline (PBS) three times and incubation
for 1 h with the appropriate secondary antibody,
enhanced chemiluminescence (Pierce Biotechnology,
Rockford, USA) was used for protein visualization.
Immunohistochemistry
Paraffin sections (4 μm thick) were prepared, deparaffi-
nized in xylene, and then hydrated through graded series
of ethanol concentrations. Antigen retrieval was per-
formed by heating the sections for 10 min at 100°C in
0.01 M citrate buffer (pH 6.0), endogenous peroxidase
activity was quenched with 3% H2O2 for 15 min, and
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blocking serum for 10 min. The sections were then incu-
bated with mouse anti-human GKN1 (1:300, Abnova) at
room temperature for 2 h. Then, a 2-step detection
method was used according to the manufacturer’s
instructions (EnVision™ Detection Kit, Gene Tech Co.,
China) by incubation of the tissue with the ChemMate™
EnVision™/HRP for 30 min at room temperature. The
reaction was visualized by the CheMate™ DAB plus
Chromogen. Lastly, the sections were counterstained
with hematoxylin solution. Negative controls were per-
formed by staining with primary antibody.
The stained sections were evaluated and scored for
staining intensity and% of staining under a light micro-
scope, i.e., percentage of staining was documented as 0
(<5%), 1 (5%-25%), 2 (26%-50%), 3 (51%-75%), and 4
(>75%). Staining intensity was documented as 0 (no
immunostaining), 1 (weak), 2 (moderate), and 3 (strong).
The value of these two scores were added together to
garner a final score for each case: a scale of 0 (score less
than 2), 1+ (score range from 2 to 3), 2+ (score range
from 4 to 5), and 3+ (score range from 6 to 7). Immu-
nostaining was assessed by an experienced pathologist
who was blinded to the clinical data of the patients.
Construction of GKN1 expression vector for gene
transfection
GKN1 cDNA was amplified from total RNA of the normal
gastric mucosa using PCR. GKN1 CDS fragments with
SalI and BamHI restriction sites were then inserted into
the pBudCE4.1 vector (Invitrogen, Carlsbad, CA, USA)
using a DNA ligation kit from TaKaRa (Dalian, China).
After transformation into DH5α E. Coli competent cells,
the plasmid was amplified and the DNA sequence was
then confirmed. To generate gastric cancer cells expres-
sing GKN1, gastric cancer AGS cells were grown to
50–75% confluency in a six-well plate, washed twice with
RPMI lacking supplements (RPMS/LS), and subjected to
the Lipofectamine-mediated transfection according to the
manufacturer’s protocol (Invitrogen). The GKN1 trans-
fected gastric cancer cells were then selected in medium
containing Zeocin (Invitrogen). After the transfected cells
formed individual cell colonies, stable cells were obtained
and then confirmed for GKN1 expression by using
RT-PCR and Western blot analyses.
Cell viability (MTT) assay
To detect changes in tumor cell viability after GKN1
transfection, a total of 1 × 104 trypsin-dispersed cells in
0.1 mL culture medium was seeded into each well of a
96-well plate, and cultured for 24 h or 48 h. Next, 20 μL
of MTT (5 g/L from Sigma-Aldrich, St. Louis, USA) was
added to each well and incubated for additional 4 h at
37°C. Culture medium was then replaced with 200 μL ofdimethyl sulfoxide (DMSO) and the absorbance rate was
determined using an ELISA reader at 490 nm. Cell
growth inhibition rate was calculated as (the value of ex-
perimental group OD /the value of control group
OD) × 100%.
Annexin V apoptosis assay
To detect tumor cell apoptosis, the GKN1 transfected
tumor cells were seeded into 60-mm diameter culture
plates, and cultured for 24 h and 48 h. The apoptotic rates
were analyzed by flow cytometry using an annexin
V-FITC/PI kit. Staining was performed according to the
manufacturer’s instructions, and flow cytometry was con-
ducted with a flow cytometer (Beckman-Coulter, Brea,
USA). Cells with annexin V (−) and PI (−) were deemed
viable cells. Cells with annexin V (+) and PI (−) were
deemed early apoptotic cells. Cells with both annexin
V (+) and PI (+) were deemed late apoptotic cells.
TUNEL assay
To identify apoptosis in the transfected cells, we utilized
the dead-end colorimetric TUNEL system kit (Promega,
Madison, USA) to measure DNA fragmentation and
caspase-3 activation in the GKN1 transfected cells,
according to the manufacturer’s instructions. Briefly,
cells were fixed in 4% paraformaldehyde solution for
25 min at room temperature, rinsed in PBS, and per-
meabilized by incubating the slides in 0.2% Triton X-100
solution. Cells were then incubated with a terminal
deoxynucleotidyl transferase (TdT) reaction mixture
containing biotinylated nucleotides and TdT at 37°C for
60 min, and rinsed with 1 × SSC (sodium chloride-
sodium citrate buffer) and PBS. Next, streptavidin HRP
was added to the cells, and the cell slides were stained
with 3,30-diaminobenzidine color solution. Finally, cells
were examined under a light microscope and the num-
ber of positive cells was counted and summarized from
a total of 10 high power fields.
Cell cycle analysis
To analyze cell cycle distribution, transfected cells were
grown and treated with 25 M olomoucine (Santa Cruz
Biotechnologies, Santa Cruz, USA) for 1 h, and then
incubated with regular culture medium for an additional
1 h [13]. Cells were then collected and subjected to cell
cycle analysis by flow cytometry as described in the pre-
vious section.
Sensitivity to 5-FU treatment
To detect the role of GKN1 in mediating sensitivity of gas-
tric cancer cells to 5-FU treatment, we grew and treated
GKN1 transfected tumor cells with 5-FU (Sigma) or DMSO
for 24 h and 48 h. Concentrations of 5-FU ranged from
Figure 1 Down regulation of GKN1 in gastric cancer cell lines and gastric tissue specimens. GKN1 RNA and protein were extracted from
tumor cell lines and gastric tissue samples and then subjected to RT-PCR and Western blotting analysis. A: GKN1 expression in gastric cancer cell
lines. GKN1 mRNA and protein were absent in the cell lines except for mRNA was weakly expressed in MKN28 cells. Normal gastric mucosa (N)
was also detected as control group. B: GKN1 expression in gastric tissue specimens. Expression of GKN1 mRNA and protein were significant
down-regulated or even absent in gastric cancer tissues but abundant in the corresponding distant non-cancerous tissues (CDNT).
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detected by flow cytometry as previously described.
cDNA microarray analysis
To perform cDNA microarray analysis, total cellular
RNA from GKN1-transfected and vector-control tumor
cells were isolated with the TrizolW Reagent (Invitrogen).
RNA was then reversely transcribed into cDNA using
the TrueLabeling-AMP Linear RNA amplification kit
(Superarray, Frederick, MD, USA), and then converted
into biotin-labeled cRNA using biotin-16-UTP and an
in vitro transcription kit (Roche, Basel, Switzerland). The
newly synthesized cRNA probes were then purified with
the ArrayGrade cRNA cleanup kit (Superarray) and then
added to the pretreated Oligo GEArrays Human Apoptosis
Microarray (OHS-012 from Superarray) that contains 112
apoptosis-related genes. The microarray was then hybri-
dized overnight at 42oC. The next day, the hybridized
arrays were washed and detected by chemiluminescence
according to the manufacturer’s instructions (Pierce). The
data were analyzed using GEArray Expression Analysis
software (Superarray). If spot intensity increased by moreTable 2 GKN1 expression detected by
immunohistochemistry in gastric tissues
Histological type Number of patient - + ++ +++ P value1
Normal gastric mucosa 20 0 0 0 20 < 0.05
Atrophic gastritis 40 0 15 20 5
Intestinal metaplasia 40 21 19 0 0
Dysplastic lesion 40 26 14 0 0
Gastric cancer 39 34 5 0 0
1Comparison between healthy volunteers, atrophic gastritis, intestinal
metaplasia, dysplasia and gastric cancer tissues, P < 0.05.than two fold, this gene was deemed upregulated. In con-
trast, if spot intensity decreased by more than two fold, the
gene was deemed downregulated.Statistical analysis
All quantitative data were expressed as mean ± SD and
analyzed using Student t-tests. The differential expression
of GKN1 among different groups was determined by
Kruskal-Wallis test. All statistical analyses were performed
using the SPSS statistical software package (version 11.0,
SPSS Inc. Chicago, USA). A P value of < 0.05 was consi-
dered statistically significant.Results
Expression of GKN1 in cancer cell lines and gastric tissue
specimens
We first performed RT-PCR and immunoblot analysis to
detect expression of GKN1 mRNA and protein levels in
cancer cell lines and tissue specimens. We found that
GKN1 mRNA was weakly expressed in gastric cancer
MKN 28 cells, and was absence in AGS, N87, MKN45,
SNU16, SNU1, and KATO cells (Figure 1A). The GKN1
protein was also not detectable in any of the seven cell
lines (Figure 1A). In contrast, GKN1 mRNA and protein
were abundance in normal gastric epithelial cells that
were obtained from healthy volunteers (Figure 1B). In 39
gastric cancer tissues, GKN1 mRNA was only weakly
expressed in 3 tissues, and absence in the remaining 36
tissues. GKN1 protein was weakly expressed in 2 gastric
cancer tissues, and absence in the remaining 37 tissues.
However, GKN1 mRNA and protein were abundantly
expressed in all of the 39 corresponding distant non-
cancerous tissues (Figure 1B).
Figure 2 Immunohistochemical detection of GKN1 protein in gastric tissue specimens. Paraffin sections were immunostained with
anti-GKN1 antibody and reviewed for GKN1 levels. GKN1 progressively decreased from normal gastric mucosa, atrophic gastritis, intestinal
metaplasia, and dysplasia to gastric cancer. A: normal gastric mucosa; B: atrophic gastritis; C: intestinal metaplasia; D: dysplasia; E, gastric cancer; F,
the corresponding distant non-cancerous tissue.
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tissue sections of normal gastric mucosae (from healthy
volunteers), atrophic gastritis, intestinal metaplasia, dys-
plasia, and gastric cancer and their corresponding dis-
tant non-cancerous mucosae. We found that the GKN1
protein was abundantly expressed in the upper glandular
layer of the top one third superficial epithelium, while
expression of GKN1 protein was progressively down
regulated from normal gastric mucosa, atrophic gastritis,
intestinal metaplasia and dysplasia, to gastric cancerFigure 3 Suppression of cancer cell viability by GKN1. The GKN1
or vector transfected gastric cancer cells were grown and subjected
to MTT assay. The data showed that viability of AGS cells with GKN1
transfection was significantly decreased compared to the cells with
vector transfection in 24 h (74.6%) and 48 h (71.7%).(Table 2) (Figure 2). This reduction in expression was
statistically significant (p < 0.05).Transfection of GKN1 reduced gastric cell proliferation
Next, we determined whether restoration of GKN1 ex-
pression would suppress gastric cancer AGS cells viabil-
ity. To this end, we generated AGS cells that stably
expressed GKN1 expression was confirmed by RT-PCR
and Weston blotting. Cell viability (MTT) assays showed
that AGS cells stably expressing GKN1 grew at a much
slower rate compared to the vector-transfected control
cells in both 24 hour and 48 hour cultures (Figure 3).
This data clearly indicate that restoration of GKN1 ex-
pression inhibits AGS cell proliferation.Effect of GKN1 on AGS cell apoptosis and cell cycle
re-distribution
We examined whether inhibition of cell proliferation by
GKN1 was due to the induction of apoptosis. To this
end, we examined the levels of apoptotic cells using flow
cytometry, and found that compared to the vector trans-
fected cells, GKN1 transfected AGS cells were apoptotic
(Figure 4A). The TUNEL assay demonstrated that en-
dogenous GKN1 significantly induced apoptosis in AGS
cells, and examination of morphology demonstrated that
the nuclei of GKN1 transfected tumor cells exhibited
condensation and fragmentation (Figure 4B).
Figure 4 Apoptosis induction of gastric cancer cell by GKN1. A: Flow cytometric assay. The GKN1 or vector transfected gastric cancer AGS
cells were grown and subjected to flow cytometry assay for detection of apoptosis; B: TUNEL assay. The GKN1 or vector transfected gastric cancer
cells were grown on glass slides and then subjected to TUNEL assay.
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cells, because suppression of cell viability is closely related
to regulation of the cell cycle. Olomoucine, a purine deriva-
tive, is a cyclin-dependent kinase (CDK) inhibitor, thus we
used it to enrich parental AGS cells in the G1 phase. Specif-
ically, cells were arrested in the cell cycle with 1 h olomou-
cine treatment and continued to incubate for another 1 h
without olomoucine. The cell cycle distribution of GKN1
transfected cells changed from 41.9% of G1 and 35.0% of S
phase to 41.2% of G1 and 28.7% of S phase of the cell
cycles. Similarly, the cell cycle distribution of vector-
transfected cells changed from 47.2% G1 and 29.1% of S
phase to 44.1%G1 and 25.3% of S phase of the cell cycles
(Figure 5). These data demonstrate that GKN1 is unable to
arrest AGS cells in the G1-S transition phase of cells.
GKN1 enhanced tumor cell sensitivity to 5-FU mediated
apoptosis
Clinically, 5-FU is routinely used in the treatment of gas-
tric cancer. In this study, we assessed whether presenceof GKN1 could enhance sensitivity of gastric cancer cells
to 5-FU treatment. Flow cytometry was used to detect
apoptosis rate after 24 hours and 48 hours (Table 3) with
different concentrations of 5-FU in the GKN1 trans-
fected cells. The results showed that apoptosis was sig-
nificantly induced in GKN1 transfected cells, in a time
and dose-dependent manner, compared to the vector
transfected cells (Table 3; Figure 6).GKN1 modulation of apoptosis-related gene expression
So far, we had demonstrated that GKN1 expression
was able to induce apoptosis in gastric cancer cells.
We therefore profiled the expression change of
apoptosis-related genes in GKN1 transfected and vec-
tor transfected AGS cells by cDNA microarray. The
Oligo GEArray-Human Apoptosis Microarray (OHS-
012 from Superarray) contains 112 apoptosis-related
genes. After hybridization of RNA probes from GKN1
or vector transfected AGS cells to the array, we could
Figure 5 Effect of GKN1 on cell cycle re-distribution. The GKN1 or vector transfected AGS cells were arrested in the cell cycle with 1 h
olomoucine treatment and continued to incubate for another 1 h without olomoucine. A: after 1 h olomoucine treatment; B: an additional hour
incubation without olomoucine.
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GKN1 transfected and control cells. Specifically, a total
of 16 genes were downregulated, and 3 genes were
upregulated after restoration of GKN1 expression in
AGS cells compared to the control cells (Table 4).
Discussion
In the current study, we investigated expression of
GKN1 mRNA and protein in tissue specimens from nor-
mal gastric mucosa, atrophic gastritis, intestinal meta-
plasia, dysplastic lesions, and gastric cancer. We found
that GKN1 expression was progressively downregulatedand lost from precancerous to cancerous tissues, indicat-
ing that the loss of GKN1 expression may contribute
to gastric carcinogenesis. Previous studies showed
decreased GKN1 expression in gastric cancer [5,14]. Our
current study, for the first time, demonstrated the pro-
gressive loss of GKN1 mRNA and protein from normal
to precancerous and cancer tissue specimens, indicating
the role of GKN1 in gastric cancer homeostasis and al-
teration of GKN1 expression in gastric cancer.
To further investigate the possible biological functions
of GKN1 in gastric cancer, we successfully cloned and
transfected GKN1 into gastric cancer AGS cells that do
Figure 6 GKN1 enhanced tumor cell sensitivity to 5-FU-mediated apoptosis. The GKN1 or vector transfected gastric cancer cells were
grown and treated with different doses of 5-Fu in 24 and 48 h. After that, these cells were subjected to flow cytometry assay for apoptosis.
A: 5-Fu treatment for 24 h; B: 5-Fu treatment for 48 h.
Table 4 Changed expression of apoptosis-related genes
in GKN1-transfected AGS cells
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GKN1 expression suppressed tumor cell viability and
induced them to undergo apoptosis and enhanced effects
of 5-FU on gastric cancer cells. These data indicate the
role of GKN1 in gastric cancer and could be further devel-
oped as a novel target for control of gastric cancer.
The following data of flow cytometry and TUNEL
assay showed that GKN1 may induce apoptosis in cancer
cells. These data were consistent with the previous stud-
ies [15,16]. The regulation of cell cycle redistribution
closely correlated with suppression of cancer cells. After
GNK1 transfected, AGS cells were treated with olomou-
cine, a CDK inhibitor, to enrich cells at G1 phase of the
cell cycle. But GKN1 was unable to hold cells in the
G1-S transition phase, suggesting that GKN1 may not
affect the cell cycle. Nevertheless, other studies found
that overexpression of GKN1 resulted in cell cycle arrest
at G1 phase [17] or G2/M phase of the cell cycles [18].
The reason for this discrepancy is unclear, but may be
because that the exogenous GKN1 protein was not equal
to the endogenous protein in regulation of cell pheno-
types or functions. Our current study using the gene
transfection technique demonstrated that induction of





0.25 mmol/L 0.5 mmol/L 1.0 mmol/L
Vector transfected 24 5.53 ± 0.06 7.70 ± 0.10 9.57 ± 0.21
GKN1 transfected 24 13.03 ± 0.40 14.93 ± 0.15 19.73 ± 0.23
Vector transfected 48 8.23 ± 0.21 12.33 ± 0.21 14.33 ± 0.06
GKN1 transfected 48 18.13 ± 0.72 23.30 ± 0.79 34.83 ± 0.67AGS cells. However, further studies are needed to ex-
plore this discrepancy.
Both the previous studies [5,9] and our current immu-
nohistochemical data showed that the GKN1 protein
was expressed in the top layers of gastric mucosa and
glands, but was absent in the deeper layer of the mucosa
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in maintenance of gastric mucosa homeostasis [19]. It is
because the top layers of the epithelium are committed
to apoptosis process in physiological condition. However,
other studies suggested that GKN1 may be secreted
from epithelial cells, and have functions in both para-
crine and autocrine systems [6] in control of normal cell
growth, differentiation, and apoptosis.
In addition, this study demonstrated that GKN1 was
able to increase the sensitivity of gastric cancer cells to
5-FU treatment. This finding suggested that GKN1 may
be useful as an adjuvant target in combination with
other chemotherapeutical agents in the treatment of gas-
tric cancer. 5-FU has been a widely used as a che-
motherapeutic agent in treating patients with gastric
cancer. It is a pyrimidine analogue and can incorporate
into DNA or RNA for the induction of cell cycle arrest
and apoptosis through inhibition of DNA duplication in
tumor cells. In this regard, GKN1 could induce cell
apoptosis, thus GKN1 could enhance 5-FU antitumor
activity in gastric cancer cells. This result may partially
explain the reason that patients who have lost GKN1 ex-
pression have shorter overall survival [20]. However, it
remains to be determined how GKN1 is able to induce
apoptosis in gastric cancer cells.
Our preliminary data revealed that GKN1 expression
was able to modulate expression of several apoptosis-
related genes using a cDNA microarray analysis. Of the
112 genes covered by the Oligo GEArrays Human Apop-
tosis Microarray, the expression of 19 genes may directly
affect by GKN1. However, some of these screening genes
(such as BAX and BCL2A1) may be indirectly or even
not affected or regulated by GKN1 protein [14,21]. Con-
sidering limitations of the microarray analysis, these
screening genes need to be verified by qRT-PCR or west-
ern blot analyses in the further study.Conclusions
In summary, expression of GKN1 mRNA and protein was
progressively downregulated from the normal mucosa,
precancerous to cancerous gastric tissues. Restoration of
GKN1 expression induced gastric cancer cells to undergo
apoptosis, and enhanced sensitivity to 5-FU-induced
apoptosis. These data indicate that GKN1 plays a role in
regulation of gastric epithelial homeostasis and that lost
GKN1 expression could contribute to gastric cancer
development.Abbreviations
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